{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:30:49Z","timestamp":1793068249378,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81570765"],"award-info":[{"award-number":["81570765"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"345 Talent Project of ShengJing Hospital of China Medical University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod Health"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multiple oral insulin-sensitizing agents, such as metformin, thiazolidinediones, inositols, and berberine, have been proven safe and efficacious in improving the endocrine, metabolic, and reproductive abnormalities seen in polycystic ovary syndrome (PCOS), providing more options for healthcare providers and patients. These oral insulin sensitizers are more convenient, practical, and economic than agents that need to be injected. A comparison of the clinical effectiveness of the four different classes of oral insulin sensitizers in PCOS has not been explored, leading to clinical uncertainty about the optimal treatment pathway. The present study aims to compare the effects of oral insulin sensitizers on endocrine and metabolic profiles in women with PCOS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We identified randomized controlled trials for PCOS from a variety of databases, published from January 2005 to October 2020. Outcomes included changes in menstrual frequency, improvements in hyperandrogenism and glucolipid metabolism and adverse side effects. A random-effects network meta-analysis was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-two trials comprising 1079 patients with PCOS were included in this study. Compared with metformin, treatment with myo-inositol\u2009+\u2009\n                      <jats:sc>d<\/jats:sc>\n                      -chiro-inositol was associated with a greater improvement in menstrual frequency (odds ratio 14.70 [95% confidence interval (CI) 2.31\u201393.58]). Myo-inositol\u2009+\u2009\n                      <jats:sc>d<\/jats:sc>\n                      -chiro-inositol and metformin\u2009+\u2009thiazolidinediones combination therapies were superior to respective monotherapies in reducing total testosterone levels. Thiazolidinediones, metformin\u2009+\u2009thiazolidinediones, and myo-inositol\u2009+\u2009\n                      <jats:sc>d<\/jats:sc>\n                      -chiro-inositol were associated with a lower insulin resistance index (HOMA-IR) compared with that in metformin alone (mean differences: \u2212\u20090.72 [95% CI (\u2212\u20091.11)\u2013(\u2212\u20090.34)] to \u2212\u20090.89 [95% CI (\u2212\u20091.460)\u2013(\u2212\u20090.32)]). Metformin\u2009+\u2009thiazolidinediones treatment was associated with lower triglyceride levels compared with that in metformin and thiazolidinediones monotherapy, while thiazolidinediones was superior to metformin in increasing high-density lipoprotein cholesterol and decreasing fasting plasma glucose, triglycerides, low-density lipoprotein cholesterol, and gastrointestinal adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Ours is the first study to report that for women with PCOS, myo-inositol combined with\n                      <jats:sc>d<\/jats:sc>\n                      -chiro-inositol and metformin combined with thiazolidinediones appear superior to metformin alone in improving insulin resistance and decreasing total testosterone. Myo-inositol combined with\n                      <jats:sc>d<\/jats:sc>\n                      -chiro-inositol is particularly efficacious in menstrual recovery. Thiazolidinediones and metformin combined with thiazolidinediones improve lipid metabolism better than metformin alone.\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial registration<\/jats:italic>\n                      PROSPERO CRD42020211524\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12978-021-01207-7","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T05:02:59Z","timestamp":1629262979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":104,"title":["Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis"],"prefix":"10.1186","volume":"18","author":[{"given":"Han","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9694-6591","authenticated-orcid":false,"given":"Bing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,18]]},"reference":[{"issue":"2","key":"1207_CR1","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1038\/nrdp.2016.57","volume":"267","author":"R Azziz","year":"2016","unstructured":"Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, Lizneva D, Natterson-Horowtiz B, Teede HJ, Yildiz BO. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;267(2):2056\u2013676. https:\/\/doi.org\/10.1038\/nrdp.2016.57.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"1207_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.fertnstert.2016.05.003","volume":"106","author":"D Lizneva","year":"2016","unstructured":"Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106(1):6\u201315. https:\/\/doi.org\/10.1016\/j.fertnstert.2016.05.003.","journal-title":"Fertil Steril"},{"issue":"3","key":"1207_CR3","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.fertnstert.2018.05.004","volume":"110","author":"HJ Teede","year":"2018","unstructured":"Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Piltonen T, Norman RJ, International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018;110(3):364\u201379. https:\/\/doi.org\/10.1016\/j.fertnstert.2018.05.004.","journal-title":"Fertil Steril"},{"key":"1207_CR4","doi-asserted-by":"publisher","first-page":"516","DOI":"10.3389\/fendo.2020.00516","volume":"11","author":"A Aversa","year":"2020","unstructured":"Aversa A, La Vignera S, Rago R, Gambineri A, Nappi RE, Calogero AE, Ferlin A. Fundamental concepts and novel aspects of polycystic ovarian syndrome: expert consensus resolutions. Front Endocrinol (Lausanne). 2020;11:516. https:\/\/doi.org\/10.3389\/fendo.2020.00516.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1207_CR5","doi-asserted-by":"publisher","unstructured":"McCartney CR, Marshall JC. CLINICAL PRACTICE. Polycystic Ovary Syndrome. N Engl J Med. 2016;375(1):54\u201364. https:\/\/doi.org\/10.1056\/NEJMcp1514916","DOI":"10.1056\/NEJMcp1514916"},{"issue":"2","key":"1207_CR6","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1007\/s12020-014-0311-1","volume":"48","author":"P Renato","year":"2015","unstructured":"Renato P. Metformin in women with PCOS, Pros. Endocrine. 2015;48(2):422\u20136. https:\/\/doi.org\/10.1007\/s12020-014-0311-1.","journal-title":"Endocrine"},{"issue":"7","key":"1207_CR7","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097.","journal-title":"PLoS Med"},{"key":"1207_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1472-6947-7-16","volume":"7","author":"C Schardt","year":"2007","unstructured":"Schardt C, Adams MB, Owens T, Keitz S, Fontelo P. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak. 2007;7:16. https:\/\/doi.org\/10.1186\/1472-6947-7-16.","journal-title":"BMC Med Inform Decis Mak"},{"issue":"1","key":"1207_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/humrep\/deh098","volume":"19","author":"Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group","year":"2004","unstructured":"Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41\u20137. https:\/\/doi.org\/10.1093\/humrep\/deh098.","journal-title":"Hum Reprod"},{"issue":"11","key":"1207_CR10","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.1210\/jc.2006-0178","volume":"91","author":"R Azziz","year":"2006","unstructured":"Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF, Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006;91(11):4237\u201345. https:\/\/doi.org\/10.1210\/jc.2006-0178.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1207_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3760\/cma.j.issn.1000-6699.2018.01.001","volume":"34","author":"Chinese Endocrinologist Association","year":"2018","unstructured":"Chinese Endocrinologist Association, Chinese Medical Doctor Association. Endocrinologist consensus on the management of polycystic ovary syndrome. Chin J Endocrinol Metab. 2018;34(1):1\u20137. https:\/\/doi.org\/10.3760\/cma.j.issn.1000-6699.2018.01.001.","journal-title":"Chin J Endocrinol Metab"},{"key":"1207_CR12","unstructured":"Zawadri J. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. Polycystic ovary syndrome. Current issues in endocrinology and metabolism. 1992."},{"issue":"1","key":"1207_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.dsx.2007.12.003","volume":"2","author":"J Ahmad","year":"2008","unstructured":"Ahmad J, Shukla N, Khan AR, Ahmed F, Siddiqui MA. Comparison of metabolic effects of metformin and rosiglitazone in the management of polycystic ovary syndrome [PCOS]: a prospective, parallel, randomized, open-label study. Diabetes Metab Syndr. 2008;2(1):37\u201346. https:\/\/doi.org\/10.1016\/j.dsx.2007.12.003.","journal-title":"Diabetes Metab Syndr"},{"issue":"2","key":"1207_CR14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3109\/01443615.2012.745839","volume":"33","author":"L Mohiyiddeen","year":"2013","unstructured":"Mohiyiddeen L, Watson AJ, Apostolopoulos NV, Berry R, Alexandraki KI, Jude EB. Effects of low-dose metformin and rosiglitazone on biochemical, clinical, metabolic and biophysical outcomes in polycystic ovary syndrome. J Obstet Gynaecol. 2013;33(2):165\u201370. https:\/\/doi.org\/10.3109\/01443615.2012.745839.","journal-title":"J Obstet Gynaecol"},{"issue":"12","key":"1207_CR15","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1093\/humrep\/dei258","volume":"20","author":"M Yilmaz","year":"2005","unstructured":"Yilmaz M, Bukan N, Ayvaz G, Karako\u00e7 A, T\u00f6r\u00fcner F, Cakir N, Arslan M. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Hum Reprod. 2005;20(12):3333\u201340. https:\/\/doi.org\/10.1093\/humrep\/dei258.","journal-title":"Hum Reprod"},{"issue":"5","key":"1207_CR16","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s13224-012-0183-3","volume":"62","author":"S Sangeeta","year":"2012","unstructured":"Sangeeta S. Metformin and pioglitazone in polycystic ovarian syndrome: a comparative study. J Obstet Gynaecol India. 2012;62(5):551\u20136. https:\/\/doi.org\/10.1007\/s13224-012-0183-3.","journal-title":"J Obstet Gynaecol India"},{"issue":"1","key":"1207_CR17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.fertnstert.2010.06.058","volume":"95","author":"KK Naka","year":"2011","unstructured":"Naka KK, Kalantaridou SN, Kravariti M, Bechlioulis A, Kazakos N, Calis KA, Makrigiannakis A, Katsouras CS, Chrousos GP, Tsatsoulis A, Michalis LK. Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study. Fertil Steril. 2011;95(1):203\u20139. https:\/\/doi.org\/10.1016\/j.fertnstert.2010.06.058.","journal-title":"Fertil Steril"},{"issue":"4","key":"1207_CR18","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1530\/EJE-08-0507","volume":"159","author":"M Jensterle","year":"2008","unstructured":"Jensterle M, Sebestjen M, Janez A, Prezelj J, Kocjan T, Keber I, Pfeifer M. Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome. Eur J Endocrinol. 2008;159(4):399\u2013406. https:\/\/doi.org\/10.1530\/EJE-08-0507.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1207_CR19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1677\/joe.1.05844","volume":"184","author":"C Ortega-Gonz\u00e1lez","year":"2005","unstructured":"Ortega-Gonz\u00e1lez C, Cardoza L, Couti\u00f1o B, Hidalgo R, Arteaga-Troncoso G, Parra A. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome. J Endocrinol. 2005;184(1):233\u20139. https:\/\/doi.org\/10.1677\/joe.1.05844.","journal-title":"J Endocrinol"},{"issue":"11","key":"1207_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.13283\/j.cnki.xdfckjz.2020.11.031","volume":"29","author":"H Zeng","year":"2020","unstructured":"Zeng H, Huang Y, Wu J, Xie TQ, Liu DK, Huang QL, Chen Z, Liu JP. Effects of pioglitazone hydrochloride and metformin hydrochloride tablets on metabolic parameters and hormones in polycystic ovary syndrome. Prog Obstet Gynecol. 2020;29(11):7\u201310. https:\/\/doi.org\/10.13283\/j.cnki.xdfckjz.2020.11.031.","journal-title":"Prog Obstet Gynecol"},{"key":"1207_CR21","doi-asserted-by":"publisher","DOI":"10.7539\/j.issn.1672-2981.2014.02.023","author":"X Wang","year":"2014","unstructured":"Wang X, Gao S, Zhang X. Metformin and pioglitazone plus metformin for patients with polycystic ovary syndrome combined with insulin resistance. Cent South Pharm. 2014. https:\/\/doi.org\/10.7539\/j.issn.1672-2981.2014.02.023.","journal-title":"Cent South Pharm"},{"key":"1207_CR22","doi-asserted-by":"publisher","first-page":"148","DOI":"10.11675\/j.issn.0253-4304.2019.02.02","volume":"41","author":"N Liang","year":"2019","unstructured":"Liang N, Zhang Z. Effects of metformin and pioglitazone on sexual hormones and metabolic level in patients with polycystic ovary syndrome. Guangxi Med J. 2019;41:148\u201352. https:\/\/doi.org\/10.11675\/j.issn.0253-4304.2019.02.02.","journal-title":"Guangxi Med J"},{"issue":"12","key":"1207_CR23","doi-asserted-by":"crossref","first-page":"743","DOI":"10.29252\/ijrm.14.12.743","volume":"14","author":"SM Sohrevardi","year":"2016","unstructured":"Sohrevardi SM, Nosouhi F, Hossein Khalilzade S, Kafaie P, Karimi-Zarchi M, Halvaei I, Mohsenzadeh M. Evaluating the effect of insulin sensitizers metformin and pioglitazone alone and in combination on women with polycystic ovary syndrome: an RCT. Int J Reprod Biomed. 2016;14(12):743\u201354.","journal-title":"Int J Reprod Biomed"},{"issue":"2","key":"1207_CR24","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/cen.13366","volume":"87","author":"M Jamilian","year":"2017","unstructured":"Jamilian M, Farhat P, Foroozanfard F, Afshar Ebrahimi F, Aghadavod E, Bahmani F, Badehnoosh B, Jamilian H, Asemi Z. Comparison of myo-inositol and metforminon clinical, metabolic and genetic parameters in polycystic ovary syndrome: a randomized controlled clinical trial. Clin Endocrinol. 2017;87(2):194\u2013200. https:\/\/doi.org\/10.1111\/cen.13366.","journal-title":"Clin Endocrinol"},{"issue":"5","key":"1207_CR25","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1080\/09513590.2018.1540570","volume":"35","author":"M Shokrpour","year":"2019","unstructured":"Shokrpour M, Foroozanfard F, Afshar Ebrahimi F, Vahedpoor Z, Aghadavod E, Ghaderi A, Asemi Z. Comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome: a randomized controlled clinical trial. Gynecol Endocrinol. 2019;35(5):406\u201311. https:\/\/doi.org\/10.1080\/09513590.2018.1540570.","journal-title":"Gynecol Endocrinol"},{"issue":"1","key":"1207_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/09513590.2016.1236078","volume":"33","author":"F Fruzzetti","year":"2017","unstructured":"Fruzzetti F, Perini D, Russo M, Bucci F, Gadducci A. Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS). Gynecol Endocrinol. 2017;33(1):39\u201342. https:\/\/doi.org\/10.1080\/09513590.2016.1236078.","journal-title":"Gynecol Endocrinol"},{"issue":"4","key":"1207_CR27","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.13040\/IJPSR.0975-8232.8(4).1664-70","volume":"8","author":"J Nehra","year":"2017","unstructured":"Nehra J, Kaushal J, Singhal SR, Ghalaut VS. A comparative study of myo inositol versus metformin on biochemical profile in polycystic ovarian syndrome in women. Int J Pharm Res. 2017;8(4):1664\u201370. https:\/\/doi.org\/10.13040\/IJPSR.0975-8232.8(4).1664-70.","journal-title":"Int J Pharm Res"},{"issue":"9","key":"1207_CR28","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.3760\/j.issn.1673-4777.2018.09.027","volume":"13","author":"J Du","year":"2018","unstructured":"Du J, Wu RR, Lin XF, Ke WN, Du Y. Clinical effect of myo-inositol combined with D-chiro-inositol on insulin resistant polycystic ovary syndrome. China Med. 2018;13(9):1389\u201393. https:\/\/doi.org\/10.3760\/j.issn.1673-4777.2018.09.027.","journal-title":"China Med"},{"key":"1207_CR29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3109\/09513590.2013.860120","volume":"30","author":"A Pizzo","year":"2014","unstructured":"Pizzo A, Lagan\u00e0 AS, Barbaro L. Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS. Gynecol Endocrinol. 2014;30:205\u20138. https:\/\/doi.org\/10.3109\/09513590.2013.860120.","journal-title":"Gynecol Endocrinol"},{"key":"1207_CR30","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.26355\/eurrev_201903_17278","volume":"23","author":"M Le Donne","year":"2019","unstructured":"Le Donne M, Metro D, Alibrandi A, Papa M, Benvenga S. Effects of three treatment modalities (diet, myoinositol or myoinositol associated with D-chiro-inositol) on clinical and body composition outcomes in women with polycystic ovary syndrome. Eur Rev Med Pharmacol Sci. 2019;23:2293\u2013301. https:\/\/doi.org\/10.26355\/eurrev_201903_17278.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1207_CR31","first-page":"575","volume":"16","author":"M Nordio","year":"2012","unstructured":"Nordio M, Proietti E. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. Eur Rev Med Pharmacol Sci. 2012;16:575\u201381.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"2","key":"1207_CR32","doi-asserted-by":"publisher","first-page":"172","DOI":"10.13359\/j.cnki.gzxbtcm.2017.02.006","volume":"1","author":"XB Li","year":"2017","unstructured":"Li XB, Kuang H, Luo Y, Chen QX. Clinical observation of berberine in intervening insulin resistance of polycystic ovary syndrome. J Guangzhou Univ Tradit Chin Med. 2017;1(2):172\u20137. https:\/\/doi.org\/10.13359\/j.cnki.gzxbtcm.2017.02.006.","journal-title":"J Guangzhou Univ Tradit Chin Med"},{"key":"1207_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3969\/j.issn.1001-568X.2016.10.0032","volume":"30","author":"P Wang","year":"2016","unstructured":"Wang P, Wang H, Wang Y. Clinical analysis of metformin combined with berberine in the treatment of obese polycystic ovary syndrome. Chin Prim Health Care. 2016;30:77\u20138. https:\/\/doi.org\/10.3969\/j.issn.1001-568X.2016.10.0032.","journal-title":"Chin Prim Health Care"},{"key":"1207_CR34","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3969\/j.issn.1005-5509.2011.05.034","volume":"5","author":"LX Wang","year":"2011","unstructured":"Wang LX, Kong YZ, Ren YW, Shen M. Therapeutic effect of berberine combined with dfformin for women with polycystic ovary syndrome and insulin resistance. J Zhejiang Chin Med Univ. 2011;5:713\u20135. https:\/\/doi.org\/10.3969\/j.issn.1005-5509.2011.05.034.","journal-title":"J Zhejiang Chin Med Univ"},{"key":"1207_CR35","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Emberson JR, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"issue":"5","key":"1207_CR36","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/0272989X12458724","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Mak. 2013;33(5):607\u201317. https:\/\/doi.org\/10.1177\/0272989X12458724.","journal-title":"Med Decis Mak"},{"key":"1207_CR37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"SP Hozo","year":"2005","unstructured":"Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13. https:\/\/doi.org\/10.1186\/1471-2288-5-13.","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"1207_CR38","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):163\u201371. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.03.016.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"1207_CR39","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1530\/EJE-09-0733","volume":"162","author":"E Diamanti-Kandarakis","year":"2010","unstructured":"Diamanti-Kandarakis E, Christakou CD, Kandaraki E, Economou FN. Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur J Endocrinol. 2010;162(2):193\u2013212. https:\/\/doi.org\/10.1530\/EJE-09-0733.","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"1207_CR40","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","volume":"60","author":"G Rena","year":"2017","unstructured":"Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577\u201385. https:\/\/doi.org\/10.1007\/s00125-017-4342-z.","journal-title":"Diabetologia"},{"key":"1207_CR41","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.diabres.2017.06.011","volume":"130","author":"D Macut","year":"2017","unstructured":"Macut D, Bjeki\u0107-Macut J, Raheli\u0107 D, Dokni\u0107 M. Insulin and the polycystic ovary syndrome. Diabetes Res Clin Pract. 2017;130:163\u201370. https:\/\/doi.org\/10.1016\/j.diabres.2017.06.011.","journal-title":"Diabetes Res Clin Pract"},{"key":"1207_CR42","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14304.10.1111\/dom.14304","author":"S Panunzi","year":"2020","unstructured":"Panunzi S, Maltese S, Verrastro O, Labbate L, De Gaetano A, Pompili M, Capristo E, Bornstein SR, Mingrone G. Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: a hierarchical network meta-analysis. Diabetes Obes Metab. 2020. https:\/\/doi.org\/10.1111\/dom.14304.10.1111\/dom.14304.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"1207_CR43","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s11892-019-1270-y","volume":"19","author":"HE Lebovitz","year":"2019","unstructured":"Lebovitz HE. Thiazolidinediones: the forgotten diabetes medications. Curr Diabetes Rep. 2019;19(12):151. https:\/\/doi.org\/10.1007\/s11892-019-1270-y.","journal-title":"Curr Diabetes Rep"},{"issue":"9","key":"1207_CR44","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1210\/clinem\/dgaa337","volume":"105","author":"C Xing","year":"2020","unstructured":"Xing C, Li CZ, He B. Insulin sensitizers for improving the endocrine and metabolic profile in overweight women with PCOS. J Clin Endocrinol Metab. 2020;105(9):2950\u201363. https:\/\/doi.org\/10.1210\/clinem\/dgaa337.","journal-title":"J Clin Endocrinol Metab"},{"key":"1207_CR45","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3389\/fphar.2017.00341","volume":"8","author":"MA Sortino","year":"2017","unstructured":"Sortino MA, Salomone S, Carruba MO, Drago F. Polycystic ovary syndrome: insights into the therapeutic approach with inositols. Front Pharmacol. 2017;8:341. https:\/\/doi.org\/10.3389\/fphar.2017.00341.","journal-title":"Front Pharmacol"},{"key":"1207_CR46","doi-asserted-by":"publisher","first-page":"1968450","DOI":"10.1155\/2018\/1968450","volume":"2018","author":"A Bevilacqua","year":"2018","unstructured":"Bevilacqua A, Bizzarri M. Inositols in insulin signaling and glucose metabolism. Int J Endocrinol. 2018;2018:1968450. https:\/\/doi.org\/10.1155\/2018\/1968450.","journal-title":"Int J Endocrinol"},{"issue":"23","key":"1207_CR47","doi-asserted-by":"publisher","first-page":"5491","DOI":"10.26355\/eurrev_201712_13940","volume":"21","author":"K Ravanos","year":"2017","unstructured":"Ravanos K, Monastra G, Pavlidou T, Goudakou M, Prapas N. Can high levels of D-chiro-inositol in follicular fluid exert detrimental effects on blastocyst quality? Eur Rev Med Pharmacol Sci. 2017;21(23):5491\u20138. https:\/\/doi.org\/10.26355\/eurrev_201712_13940.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"3","key":"1207_CR48","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1080\/09513590.2018.1540578","volume":"35","author":"F Facchinetti","year":"2019","unstructured":"Facchinetti F, Orr\u00f9 B, Grandi G, Unfer V. Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials. Gynecol Endocrinol. 2019;35(3):198\u2013206. https:\/\/doi.org\/10.1080\/09513590.2018.1540578.","journal-title":"Gynecol Endocrinol"},{"issue":"1","key":"1207_CR49","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1186\/s12906-017-2011-x","volume":"17","author":"S Arentz","year":"2017","unstructured":"Arentz S, Smith CA, Abbott J, Bensoussan A. Nutritional supplements and herbal medicines for women with polycystic ovary syndrome; a systematic review and meta-analysis. BMC Complement Altern Med. 2017;17(1):500. https:\/\/doi.org\/10.1186\/s12906-017-2011-x.","journal-title":"BMC Complement Altern Med"},{"issue":"11","key":"1207_CR50","doi-asserted-by":"publisher","first-page":"CD003053","DOI":"10.1002\/14651858.CD003053.pub6","volume":"11","author":"LC Morley","year":"2017","unstructured":"Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2017;11(11):CD003053. https:\/\/doi.org\/10.1002\/14651858.CD003053.pub6.","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"1207_CR51","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1080\/09513590.2017.1421632","volume":"34","author":"A Gateva","year":"2018","unstructured":"Gateva A, Unfer V, Kamenov Z. The use of inositol(s) isomers in the management of polycystic ovary syndrome: a comprehensive review. Gynecol Endocrinol. 2018;34(7):545\u201350. https:\/\/doi.org\/10.1080\/09513590.2017.1421632.","journal-title":"Gynecol Endocrinol"},{"issue":"1","key":"1207_CR52","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1530\/EJE-11-0616","volume":"166","author":"W Wei","year":"2012","unstructured":"Wei W, Zhao H, Wang A, Sui M, Liang K, Deng H, Ma Y, Zhang Y, Zhang H, Guan Y. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. Eur J Endocrinol. 2012;166(1):99\u2013105. https:\/\/doi.org\/10.1530\/EJE-11-0616.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1207_CR53","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00404-020-05450-4","volume":"301","author":"M Rondanelli","year":"2020","unstructured":"Rondanelli M, Infantino V, Riva A, Petrangolini G, Faliva MA, Peroni G, Naso M, Nichetti M, Spadaccini D, Gasparri C, Perna S. Polycystic ovary syndrome management: a review of the possible amazing role of berberine. Arch Gynecol Obstet. 2020;301(1):53\u201360. https:\/\/doi.org\/10.1007\/s00404-020-05450-4.","journal-title":"Arch Gynecol Obstet"},{"key":"1207_CR54","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.phymed.2018.09.212","volume":"50","author":"J Ju","year":"2018","unstructured":"Ju J, Li J, Lin Q, Xu H. Efficacy and safety of berberine for dyslipidaemias: a systematic review and meta-analysis of randomized clinical trials. Phytomedicine. 2018;50:25\u201334. https:\/\/doi.org\/10.1016\/j.phymed.2018.09.212.","journal-title":"Phytomedicine"},{"key":"1207_CR55","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/7918631","author":"L Xie","year":"2019","unstructured":"Xie L, Zhang D, Ma H, He H, Xia Q, Shen W, Chang H, Deng Y, Wu Q, Cong J, Wang CC, Wu X. The effect of berberine on reproduction and metabolism in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized control trials. Evid Based Complement Altern Med. 2019. https:\/\/doi.org\/10.1155\/2019\/7918631.","journal-title":"Evid Based Complement Altern Med"},{"key":"1207_CR56","doi-asserted-by":"publisher","first-page":"2532935","DOI":"10.1155\/2018\/2532935","volume":"2018","author":"MF Li","year":"2018","unstructured":"Li MF, Zhou XM, Li XL. The effect of berberine on polycystic ovary syndrome patients with insulin resistance (PCOS-IR): a meta-analysis and systematic review. Evid Based Complement Altern Med. 2018;2018:2532935. https:\/\/doi.org\/10.1155\/2018\/2532935.","journal-title":"Evid Based Complement Altern Med"}],"container-title":["Reproductive Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12978-021-01207-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12978-021-01207-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12978-021-01207-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T10:02:23Z","timestamp":1673085743000},"score":1,"resource":{"primary":{"URL":"https:\/\/reproductive-health-journal.biomedcentral.com\/articles\/10.1186\/s12978-021-01207-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,18]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1207"],"URL":"https:\/\/doi.org\/10.1186\/s12978-021-01207-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-357312\/v1","asserted-by":"object"}]},"ISSN":["1742-4755"],"issn-type":[{"value":"1742-4755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,18]]},"assertion":[{"value":"23 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"171"}}